Business Context and Reporting Period
This Form 8-K Current Report was filed by Bruker Corporation on May 19, 2015. The filing addresses a significant change in executive leadership within the finance department.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation adjustments.
Material Changes
- Departure of CFO: Charles F. Wagner, Jr., Executive Vice President and Chief Financial Officer since July 2012, resigned effective June 12, 2015, to become CFO of Ortho-Clinical Diagnostics, Inc.
- Interim Appointment: Anthony L. Mattacchione, Senior Vice President of Finance & Accounting, was appointed Interim CFO effective upon Mr. Wagner's departure.
- Compensation Adjustment: Mr. Mattacchione's base salary will increase by $8,000 per month. He is also eligible for a special bonus of $150,000 payable on March 31, 2016, subject to goal achievement.
Guidance, Outlook, and Risks
The filing states that Mr. Wagner's resignation is not the result of any dispute regarding the Company's accounting practices or financial statements. Mr. Wagner will remain in his role until June 12, 2015, to ensure an orderly transition. The Company intends to initiate a search for a permanent CFO. No financial guidance or market outlook is provided in this report.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 12, 2015).
- Confirm the terms of the interim CFO's compensation increase and performance bonus.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review the attached press release (Exhibit 99.1) for additional public commentary.